This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. Mutation of the lysine at the C-terminus of certain Fc regions to an alanine can improve the pharmacokinetic properties of a fusion protein that already has improved pharmacokinetics as a result of reduced Fc receptor binding.
Description:
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. Mutation of the lysine at the C-terminus of certain Fc regions to an alanine can improve the pharmacokinetic properties of a fusion protein that already has improved pharmacokinetics as a result of reduced Fc receptor binding. Deduction of immunogenic reactive epitopes of huKS-IL2 immunocytokme. This immunocytokine was designed for treating solid tumor. http://www.creativebiolabs.net/Anti-EpCAM-Immunocytokine-IgG-huKS-IL2-22500.htm
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
